Abstract: Psoriasis is a chronic inflammatory skin disease that may be triggered or worsened by several factors, including alcohol. A higher than average alcohol consumption is common among individuals with psoriasis. Neurobiological signaling affected by alcohol intake includes a range of neurotransmitters, such as the dopaminergic, serotonergic, and tachykinergic systems, involved in reward and drug-seeking. These neurotransmitters may also have an impact on the inflammatory processes per se in psoriasis. Future therapy may, therefore, be targeted at neurotransmitter networks involved with both alcohol intake and the inflammatory processes.
Introduction
Psoriasis is a chronic inflammatory skin disease affecting 2-5% of the population in Western countries. The disease is characterized by increased cell proliferation in the basal epidermal layer and disturbed differentiation in the apical part of the epidermis. Pathoetiological mechanisms include both innate and acquired immune systems. 1 There is a complex interplay between genetic and environmental factors linked to the severity and triggering of psoriasis. 2, 3 Such triggering/worsening factors include damage to the skin and streptococcal infection. Studies have also shown that psychological stress, due to emergency crises and family stress, may contribute to the onset of psoriasis. Other factors that can worsen psoriasis are drugs, such as beta-blockers, lithium, and interferon-α. Smoking may also have a negative effect on the disease. 4 Recently Zink et al 5 reported various forms of addiction in psoriasis, with alcohol dependence being a substantial one. The present review discusses the role of alcohol (ethanol) in psoriasis.
proinflammatory events in alcohol-induced brain vascular injury. 9 It may also activate microglia and neurons in rats. 10 Alcohol may be both an initiating and aggravating factor in inflammation. It can affect both innate and adaptive immunity. Previous studies have suggested mechanisms such as increased proinflammatory cytokines, eg, increased production of tumor necrosis factor -α (TNF-α) from peripheral blood monocytes and macrophages, and increased lymphocyte proliferation and activation, caused by alcohol. 11 Alcohol-induced liver injury in mice resulted in an impairment of skin barrier function, possibly mediated via plasma TNF-α. 12 Alcohol may also have an impact on the number and function of murine epidermal T cells. 13 The methylation changes in CD4 + T cells are greater in patients with psoriasis than in healthy control subjects. 14 Alcohol may have an impact on migration of murine dermal dendritic cells to draining lymph nodes after sensitization. 15 In female mice, alcohol caused a reduced dendritic function, compared to male mice. 16 Mast cells are believed to play a role in the pathogenesis of psoriasis, and alcohol may affect the number of mast cells as well as their degranulation. [17] [18] [19] The skin and central nervous system share a common origin through the ectoderm.
Alcohol affects the brain in several ways. Like other drugs, it stimulates the brain's reward center via several neurotransmitter systems, depending on the phase of alcohol dependency of the individual. 20 
Alcohol and psoriasis
Patients with psoriasis consume more alcohol than the general population. 21 Alcohol may affect psoriasis through several mechanisms, such as increased susceptibility to infections, stimulation of lymphocyte and keratinocyte proliferation, and production of proinflammatory cytokines.
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Only a limited number of studies have investigated the relationship between the severity of psoriasis and alcohol use. In these, mostly retrospective, studies, a positive correlation between alcohol intake and the extent of psoriasis has, in general, been reported for women. An association between total body surface area and alcohol use was found in a case-control study on women in-and out patients with mixed subtypes of psoriasis. 23 A multicenter study of 1203 inpatients with different subtypes of psoriasis demonstrated a correlation between the psoriasis area severity index (PASI) score and level of alcohol consumption, but only for women. 24 The level of alcohol use was estimated based on medical record data, and the majority of patients were social drinkers according to self-report. In a limited cross-sectional study, we have shown a correlation in women between alcohol consumption, measured by phosphatidylethanol (PEth) and Lifetime Drinking History (LDH) interview, and extent of psoriasis. 25 However, an earlier case-control study showed alcohol to be a risk factor for psoriasis in young and middle-aged men. 26 There are few prospective studies on the role of alcohol in psoriasis. In the Nurses' Health Study (NHS II), intake of non light beer in a cohort of US nurses was associated with an increased risk of developing psoriasis. 27 In 150 outpatients enrolled in a 3-month observational study, therapeutic outcome, as measured by achieving 75% PASI recovery, with conventional psoriasis therapy, was hampered due to obesity, female sex, tobacco or smoking habits, and alcohol habits. 28 In a Pakistani study on outpatients with psoriasis, PASI score was significantly associated with drinking alcohol. 29 In the Department of Dermatology, Karolinska University Hospital, Solna, we have performed a small prospective study on 22 patients with low-moderate intake of alcohol and mild-moderate extent of psoriasis, using Christmas and New Year as the exposure periods, when alcohol intake is expected to increase. 30 Although alcohol intake increased, there was only a marginal increase in the extent of psoriasis. Alcohol consumption has not only been associated with a more severe and a higher incidence of psoriasis, but also with a distinctive nature and distribution of the disease. Patients with psoriasis and alcohol overconsumption tend to have more severe inflammation, with minimal scale, typically distributed in the face, groin, and flexures, or typically hyperkeratotic lesions with a predominant acral distribution. 31 Alcohol intake may induce pruritus by lowering its threshold and thus has been suggested to increase pruritus in psoriasis. However, several studies have failed to show such an association. 25, 32, 33 A study of 95 patients with plaque psoriasis examined their alcohol intake and psychological stress and found that 17-30% of patients were rated as having alcohol problems. Thirteen percent and 18% of patients with psoriasis were classified with ongoing or previous alcohol problems, respectively, and there was a link between increased alcohol intake and increased anxiety and depression. In addition, the patients who considered that they had alcohol problems had more trouble with anxiety and depression, and also more psoriasis. 34 People with psoriasis have an increased risk of premature mortality. The reason for this is not fully understood, but is likely to be multifactorial. The most common comorbidities for patients with psoriasis are hyperlipidemia, hypertension, depression, diabetes mellitus type 2, and obesity. 35 A Finnish cohort admitted to inpatient treatment with psoriasis as the principal diagnosis showed an excess mortality caused by alcohol. Among men, these causes included alcohol-related psychosis, liver disease, and alcohol dependence, and, in women, liver disease.
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A population-based cohort study investigated whether people with psoriasis had a higher risk of alcohol-related mortality and found that patients with psoriasis had a 60% greater risk of dying due to alcohol-related causes compared to others of the same age and sex in the general population. This indicated that alcohol may be a great contributor to the premature mortality gap. The predominant causes of alcohol-related deaths were alcoholic liver disease, fibrosis and cirrhosis of the liver, and psychological and behavioral disorders due to alcohol. 37 There is an increased proportion of liver disease, both alcoholic and non alcoholic, in psoriatic patients, and the prevalence of psoriasis in patients with alcoholic liver disease is higher than the predicted value in the normal population. 31, 38 In this respect, TNF-α, a key cytokine in psoriasis pathogenesis, may have a role.
Therapeutic neurotransmitter targets
The current therapy for psoriasis per se includes topical desquamating drugs, potent topical glucocorticoids, topical calcipotriol, and, for severe disease, systemic treatments, such as UV light, methotrexate, and biologicals, such as anti-TNF-α agents. A problem with regard to classical systemic treatments, such as biologicals, is that, due to inhibition of cells that destroy invading microorganisms, alcohol intake may result in increased susceptibility to infections.
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It should also be noted that alcohol use may be associated with worse adherence to treatment of their skin disease. In addition, alcohol consumption may be used by patients with psoriasis to cope with their debilitating skin disease. 38 It may be attractive to use a neuro endocrine approach for patients with psoriasis who present with overconsumption of alcohol.
Targets for treatment of alcohol dependence per se may focus on the neuronal circuits of reward, addiction, and satisfaction, in addition to the biochemical pathways of alcohol metabolism. 20 These include dopaminergic, serotonergic, tachykinergic and acetylcholine (ACh), opioid, gamma-aminobutyric acid (GABA), and glutamatergic-mediated transmissions. Pharmacologic drugs in such systems used for treatment of alcohol dependence are: dopamine (DA) 2 receptor (R) and serotonin (5-HT)2R antagonists (eg, olanzapine), selective serotonin reuptake inhibitors (SSRIs) (eg, sertraline), 5-HT3R antagonist (ondansetron), and naltrexone. As regards the tachykinergic system, recently neurokinin (NK)-1R antagonism has been implicated in modulating alcohol consumption and reward. 39, 40 Regarding the inflammatory process in psoriasis per se, we and/or others have found receptors for biogenic amines, such as 5-HT, 41, 42 tachykinins, including the NK-1R, 43 and
ACh receptors, 44 in psoriasis. Expression of such receptors has been found in the basal and/or differentiating zones of the epidermis and on dermal inflammatory cells, while dendritic inflammatory cells in the epidermis and dermis show expression of SERT. 45 A cohort study by Thorslund et al 46 found
that patients with psoriasis who had undergone SSRI treatment were less often switched to systemic treatment. Interestingly, brainstem 5-HT transporter availability has been shown to be correlated with circulating TNF-α. 47 5-HT2R activation may suppress TNF-α-induced inflammation, 48 and polymorphism of the 5-HT2AR gene is associated with late-onset psoriasis in a Thai population.
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A relationship between DA and the pathophysiology of psoriasis has been known since the 1970s. Thus, levodopa resulted in the resolution of inverse psoriasis when being used for Parkinson's disease, possibly due to an increase in cyclic AMP. 50 Moreover, bromocriptine, a strong D2R agonist, has been used in patients with psoriasis with different results on the clinical outcome.
51-53
The anti depressive drug bupropion, a noradrenaline and DA reuptake inhibitor, has been reported to result in a reduction in psoriasis-affected skin surface. 54 N-methyl-D-aspartate is a glutamate receptor abnormally expressed in psoriasis. Disturbed expression of subunits of such receptors has been reported in the basal and apical part of the epidermis. 55, 56 GABA and GABA A R expression has previously been found mainly in inflammatory cells in psoriasis. 57 Future therapies for alcohol and psoriasis might thus be targeted at neurotransmitter networks involved with both alcohol intake and the inflammatory processes.
Conclusion
More research is needed in order to determine whether alcohol can induce or worsen psoriasis. Studies should examine whether there is a threshold to alcohol intake at which the disease worsens or debuts, and whether the type of alcohol plays a part and, if so, to what extent.
It is difficult to interpret study results, because patients with psoriasis may smoke and suffer from metabolic syndrome, ie, there are several confounders. Furthermore, the measure of alcohol intake differs in different studies, and it is, therefore, difficult to compare results and draw a valid conclusion.
There are difficulties in recruiting patients with psoriasis to participate in studies concerning the correlation of their disease with alcohol intake. Stigmatization concerning both alcohol and psoriasis may make it difficult to recruit a sufficient number of patients. In this respect, register studies or studies in which patients may answer inquiries and rate their ongoing intake of alcohol and the extent of their psoriasis anonymously would be of importance. Also, the effect of ceasing alcohol intake on the extent of the disease should be studied.
Animal experiments are warranted; however, such experiments are at present limited by the lack of a suitable animal model for psoriasis.
In addition, more prospective studies, including during seasonal periods/festivals when patients consume a higher than normal amount of different types of alcohol, may be of substantial value.
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